Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 5:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 545 matching trials from the live ClinicalTrials.gov search.
Conditions
Suicidal Ideation
Interventions
Uridine, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 55 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Heart Diseases, Aortic Stenosis, Severe
Interventions
Edwards SAPIEN 3 / SAPIEN 3 Ultra THV
Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
65 Years and older
Enrollment
901 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2032
U.S. locations
74
States / cities
Phoenix, Arizona • Burlingame, California • Los Angeles, California + 62 more
Conditions
Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
Interventions
Biopsy Procedure, Biospecimen Collection, Brentuximab Vedotin, Computed Tomography, Ipilimumab, Nivolumab, Positron Emission Tomography
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
479
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 303 more
Conditions
Clostridium Difficile Infection, Recurrent Clostridium Difficile Infection, C. Diff, CDI, Recurrent C. Diff, rCDI, C. Difficile, Recurrent CDI, FMT, Fecal Microbiota, Fecal Transplant
Interventions
CP101
Biological
Lead sponsor
Finch Research and Development LLC.
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
53
States / cities
Scottsdale, Arizona • Los Angeles, California • Murrieta, California + 47 more
Conditions
Pain
Interventions
Suzetrigine
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years and older · Female only
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma
Interventions
belinostat
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
123
States / cities
Mobile, Alabama • Tucson, Arizona • Jonesboro, Arkansas + 74 more
Conditions
Attention Deficit/Hyperactivity Disorder
Interventions
Centanafadine Hydrochloride
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
4 Years to 18 Years
Enrollment
680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
84
States / cities
Dothan, Alabama • Saraland, Alabama • Phoenix, Arizona + 62 more
Conditions
Colon Adenocarcinoma, Stage IIA Colon Cancer AJCC v7, Stage IIB Colon Cancer AJCC v7, Stage IIC Colon Cancer AJCC v7
Interventions
Bevacizumab, Fluorouracil, Leucovorin, Oxaliplatin
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
2,431 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2026
U.S. locations
910
States / cities
Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 578 more
Completed No phase listed Observational Accepts healthy volunteers

TearLab Refractive Surgery Dry Eye Study

NCT01176045
Conditions
Dry Eye Syndromes
Interventions
Not listed
Lead sponsor
TearLab Corporation
Industry
Eligibility
21 Years and older
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
8
States / cities
Fairfield, Connecticut • Westchester, Illinois • Oklahoma City, Oklahoma + 5 more
Terminated Phase 2Phase 3 Interventional Results available

Lithium for Suicidal Behavior in Mood Disorders

NCT01928446
Conditions
Depressive Disorder, Bipolar Disorder, Suicide, Suicide, Attempted
Interventions
Lithium, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Not listed
Enrollment
519 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
28
States / cities
Phoenix, Arizona • Tucson, Arizona • North Little Rock, Arkansas + 25 more
Conditions
Alcohol Use Disorder
Interventions
Semaglutide, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 80 Years
Enrollment
622 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
19
States / cities
Long Beach, California • Palo Alto, California • West Los Angeles, California + 15 more
Conditions
Prostate Cancer
Interventions
bicalutamide, flutamide, LHRH agonist (antagonist) therapy, Dose-Escalated Radiation Therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Male only
Enrollment
1,538 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2025
U.S. locations
499
States / cities
Birmingham, Alabama • Fairbanks, Alaska • Peoria, Arizona + 353 more
Conditions
Prostate Cancer
Interventions
bicalutamide, estramustine, etoposide, flutamide, goserelin, leuprolide, nilutamide, paclitaxel
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older · Male only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
91
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 60 more
Conditions
Clear Cell Renal Cell Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lymph Nodes, Metastatic Malignant Neoplasm in the Soft Tissue, Metastatic Malignant Neoplasm in the Viscera, Rhabdoid Tumor of the Kidney, Sarcomatoid Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Biospecimen Collection, Bone Scan, Cabozantinib, Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Nivolumab, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Drug · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
1,175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
858
States / cities
Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 554 more
Conditions
Extragonadal Germ Cell Tumor, Testicular Germ Cell Tumor
Interventions
arsenic trioxide
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
16 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
94
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 60 more
Conditions
Chronic Uncontrolled Gout, Gout, Uncontrolled Gout
Interventions
Pegloticase with MTX
Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
39
States / cities
Birmingham, Alabama • Anchorage, Alaska • Gilbert, Arizona + 33 more
Conditions
High Triglycerides
Interventions
NST-1024, Placebo
Drug · Other
Lead sponsor
NorthSea Therapeutics B.V.
Industry
Eligibility
18 Years to 79 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
31
States / cities
Birmingham, Alabama • Daphne, Alabama • Tempe, Arizona + 28 more
Conditions
Breast Cancer
Interventions
cyclophosphamide, docetaxel, doxorubicin hydrochloride
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years · Female only
Enrollment
2,778 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
134
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 84 more
Conditions
Cocaine-Related Disorders
Interventions
Selegiline
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years and older
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
16
States / cities
Tucson, Arizona • Berkeley, California • Los Angeles, California + 11 more
Conditions
Osteoarthritis, Degenerative
Interventions
Pulsed Low Intensity Ultrasound, Sham Comparator
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
3
States / cities
San Diego, California • Dallas, Texas • Salt Lake City, Utah
Conditions
Overactive Bladder
Interventions
Solabegron immediate release tablets, low dose, Solabegron immediate release tablets, high dose, Matching Placebo
Drug
Lead sponsor
Velicept Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
86
States / cities
Birmingham, Alabama • Gulf Shores, Alabama • Mobile, Alabama + 77 more
Conditions
Diabetic Peripheral Neuropathic Pain
Interventions
Suzetrigine
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 80 Years
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
65
States / cities
Anniston, Alabama • Daphne, Alabama • Scottsdale, Arizona + 60 more
Conditions
Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Double-Expressor Lymphoma, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Neoplastic Cells With Double Expression of MYC and BCL2 Proteins Present, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Lumbar Puncture, Positron Emission Tomography, Prednisone, Rituximab, Venetoclax, Vincristine Sulfate
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 80 Years
Enrollment
363 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
634
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 433 more
Conditions
Major Depressive Disorder
Interventions
Pexacerfont, Escitalopram, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
45
States / cities
Springdale, Arkansas • Orange, California • Upland, California + 39 more